CA-NEXON-AMERICA
16.12.2021 23:05:06 CET | Business Wire | Press release
MapleStory M , Nexon’s popular free-to-play mobile MMORPG, has officially launched its latest update, bringing the long-awaited Pathfinder class to the game alongside a flurry of winter season events and activities for Maplers to tackle. The Pathfinder update has also increased the max level to 250, and brings new daily and weekly missions, achievements, and a new mini-dungeon to the game.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216006140/en/
As of today, the sharpshooting Explorer who wields an ancient bow, Pathfinder, is available as a new playable class. Maplers who pre-registered their Pathfinder were eligible for items such as Auto Battle Charge Tickets and EXP tickets, while all players can take part in Mega Burning and On-Time/Growth Support events to help level-up a new Pathfinder quickly. As a bonus after today’s maintenance, both MapleStory M and MapleStory will be running the Pathfinder Link Event through January 19, 2022, whereby, after reaching level, 70, 120, and 140 on MapleStory M with the Pathfinder, Maplers can garner rewards in both games, including a Pathfinder outfit gift box, Ancient Relic, and more.
The Black Mage's fourth commander, Arkarium, formerly a servant under Rhinne, Maple World's Transcendent of Time, makes his debut in MapleStory M . Maplers will be able to craft all-new boss accessory Dominator Pendant using the materials acquired when defeating Arkarium.
A new map in the Arcane River has also been added, the Dreaming City Lachelein , bringing with it new quests, monsters, area items to discover, and a new Arcane force field. Mini-dungeons have also received a quality of life improvement with this update so that Maplers can auto-play multiple times by using tickets and mesos.
In addition to the events celebrating the arrival of Pathfinder, players can look forward to numerous winter seasonal events occurring throughout December and into the new year:
- I&B Burning Challenge Mission Event - From December 15, 2021 through January 19, 2022, this event returns, granting not only Ice Agent or Burning Agent player titles, but also granting daily missions for players to conquer.
- Holiday Mr. Kim’s Gift - From December 22 through December 30, 2021, tapping on Mr. Kim will reward players with special items.
-
Winter Happyville
Events
- (Various scheduled times - refer to in-game event banner or see MapleStoryM
patch notes for exact times and dates for each event.) Winter Happy Village will play host to multiple winter events throughout December and January :
- Coin Drop Event
- A Well-Behaved Child Needs A Gift!
- A Crying Child Also Needs A Gift!
- Buff Tree Event
- Great Rudolph Escape
- 2022 Countdown Event - From December 23, 2021 through January 6, 2022, players can enter the event map every day and receive EXP for ten minutes. After spending ten minutes on the map, these players will receive a countdown reward and, on January 1, Maplers can earn a special New Year reward!
- Snowflake Snowpark - From January 6 through January 18, 2022, Maplers can earn AB tickets, EXP tickets, and Gold Leaf by clearing different missions and receiving stamps.
- 2022 New Year Wheel - From January 13 through January 27, 2022, players can receive a maximum of 5 wheel tickets per day by hunting. Rewards for participating in the event include AB tickets, Luckyday scroll 5%, cubes, EXP tickets, and more.
To learn more about MapleStory M, visit the App Store or Google Play Store page and follow @PlayMapleM on Twitter for the latest updates.
Assets: Artwork
Social Media: Facebook / Instagram / Twitter / Twitch / YouTube / Discord
About MapleStory M https://maplestorym.nexon.com/
MapleStory M , launched globally on July 24, 2018, brings the nostalgic world of side-scrolling MMORPG MapleStory to mobile, offering the same endless amount of customization, immersive storylines and epic boss raids that fans have come to expect from the legendary franchise. MapleStory M quickly reached 10 million downloads within 100 days after global launch and recently celebrated its 3-year anniversary with 16 million global downloads.
About Nexon America Inc. https://www.nexon.com/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211216006140/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom